| scholarly article | Q13442814 |
| P50 | author | Stefan Zeuzem | Q28360321 |
| P2093 | author name string | Eva Herrmann | |
| Jung-Hun Lee | |||
| George Marinos | |||
| Marlene Modi | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| ribavirin | Q421862 | ||
| P304 | page(s) | 1351-1358 | |
| P577 | publication date | 2003-06-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon | |
| P478 | volume | 37 |
| Q52589911 | A New Model for the Dynamics of Hepatitis C Infection: Derivation, Analysis and Implications. |
| Q33906899 | A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease |
| Q28473678 | A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants |
| Q34759489 | A perspective on modelling hepatitis C virus infection |
| Q36306694 | A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C. |
| Q37078061 | ANALYSIS OF HEPATITIS C VIRUS INFECTION MODELS WITH HEPATOCYTE HOMEOSTASIS |
| Q28481489 | Analysis of the virus dynamics model reveals that early treatment of HCV infection may lead to the sustained virological response |
| Q43032263 | Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C. |
| Q43040809 | Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. |
| Q46454514 | Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C. |
| Q34621423 | Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy |
| Q36954043 | Clinical efficacy of the highly sensitive hepatitis C virus RNA quantitative assay in patients with relapse following interferon-based therapy with second-generation direct-acting antivirals |
| Q43040164 | Complete early virological response was highly achieved by double filtration plasmapheresis plus IFN-beta induction therapy for HCV-1b patients with relapse or no response after previous IFN therapy |
| Q43037722 | Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. |
| Q43034515 | Design evaluation and optimization for models of hepatitis C viral dynamics. |
| Q33727347 | Direct-acting antiviral agents and the path to interferon independence |
| Q50971611 | Dissolving microneedle-based intradermal delivery of interferon-α-2b. |
| Q35992420 | Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response |
| Q34726155 | Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B |
| Q42990511 | Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon alpha-2b and ribavirin |
| Q42988882 | Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. |
| Q34036824 | Early viral kinetics during hepatitis C virus genotype 6 treatment according to IL28B polymorphisms |
| Q33676349 | Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B |
| Q43040757 | Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. |
| Q42202008 | Effects of ribavirin monotherapy on the viral population in patients with chronic hepatitis C genotype 1: direct sequencing and pyrosequencing of the HCV regions |
| Q42978531 | Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection |
| Q22252850 | Estimating drug efficacy and viral dynamic parameters: HIV and HCV |
| Q27480267 | Evolution of Resistant M414T Mutants among Hepatitis C Virus Replicon Cells Treated with Polymerase Inhibitor A-782759 |
| Q34769764 | Fluvastatin inhibits hepatitis C replication in humans |
| Q26801602 | HCV Kinetic Models and Their Implications in Drug Development |
| Q75208711 | Hematopoietic growth factors for acute myelogenous leukemia |
| Q37060801 | Hepatitis C Viral Kinetics in Special Populations |
| Q35610571 | Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B. |
| Q41103902 | Hepatitis C Virus Therapy-related Skin Manifestations. |
| Q42998257 | Hepatitis C virus free-virion and immune-complex dynamics during interferon therapy with and without ribavirin in genotype-1b chronic hepatitis C patients |
| Q24297145 | Hepatitis C virus non-structural protein NS5A interacts with FKBP38 and inhibits apoptosis in Huh7 hepatoma cells |
| Q43000349 | High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C. A multicentric, randomised, controlled trial |
| Q36675798 | IFN-α subtypes: distinct biological activities in anti-viral therapy. |
| Q36073739 | Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections |
| Q39258088 | Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers |
| Q42433381 | Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients |
| Q41392572 | Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders |
| Q28482160 | Interferon-alpha subtype 11 activates NK cells and enables control of retroviral infection |
| Q38530211 | Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. |
| Q37952923 | Interferons as therapeutic agents for infectious diseases. |
| Q34444955 | Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection |
| Q37481103 | Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study |
| Q25257004 | Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients |
| Q56000943 | Mathematical Analysis of Viral Replication Dynamics and Antiviral Treatment Strategies: From Basic Models to Age-Based Multi-Scale Modeling |
| Q37138516 | Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents |
| Q28478310 | Mathematical model of viral kinetics in vitro estimates the number of E2-CD81 complexes necessary for hepatitis C virus entry |
| Q36810400 | Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents? |
| Q37940977 | Mechanism of action of ribavirin in the treatment of chronic hepatitis C. |
| Q35166521 | Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. |
| Q56935271 | Modeling HCV kinetics under therapy using PK and PD information |
| Q27485474 | Modeling hepatitis C virus dynamics: Liver regeneration and critical drug efficacy |
| Q26864673 | Modelling hepatitis C therapy--predicting effects of treatment |
| Q33870943 | Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay. |
| Q42989468 | Modelling how ribavirin improves interferon response rates in hepatitis C virus infection |
| Q27489069 | Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon α-2b |
| Q36263215 | New kinetic models for the hepatitis C virus |
| Q37636095 | Optimizing the treatment of chronic viral hepatitis C. |
| Q37032096 | Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1. |
| Q42223532 | Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial |
| Q35874153 | Peginterferon alfa-2a: a review of approved and investigational uses |
| Q24200189 | Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C |
| Q35597434 | Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. |
| Q28295063 | Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in hepatitis C Virus And HIV co-infection |
| Q42981999 | Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. |
| Q43000568 | Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders |
| Q42705363 | Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients |
| Q34208650 | Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes |
| Q43041294 | Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus |
| Q45279421 | Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection |
| Q27487771 | Polymorphism in the Human Major Histocompatibility Complex and Early Viral Decline during Treatment of Chronic Hepatitis C |
| Q34409039 | Predicting the probable outcome of treatment in HCV patients |
| Q42979354 | R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin |
| Q27478215 | Replicative Homeostasis III: implications for antiviral therapy and mechanisms of response and non-response |
| Q27481003 | Response Prediction and Treatment Tailoring for Chronic Hepatitis C Virus Genotype 1 Infection |
| Q35915616 | Review article: pegylated interferons: chemical and clinical differences |
| Q36447562 | Review article: predicting response in hepatitis C virus therapy |
| Q33987120 | Ribavirin improves early responses to peginterferon through improved interferon signaling |
| Q35748913 | Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection. |
| Q37195248 | Ribavirin in the treatment of chronic hepatitis C. |
| Q50578931 | Ribavirin mutagenesis: hidden clues in mathematical models. |
| Q33815550 | Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy |
| Q37449527 | Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. |
| Q34624732 | Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial |
| Q28484092 | Spontaneous clearance of viral infections by mesoscopic fluctuations |
| Q38796348 | Targeting the Channel Activity of Viroporins. |
| Q42981009 | The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin |
| Q50579315 | Treatment of chronic hepatitis C in patients unresponsive to interferon. Interest of re-treatment combining interferon induction therapy and ribavirin (a multicenter pilot study). |
| Q33869261 | Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage |
| Q33899320 | Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling |
| Q38073656 | Treatment of hepatitis C: how will we use viral kinetics, response-guided therapy? |
| Q43038759 | Triphasic decline of hepatitis C virus RNA during antiviral therapy |
| Q34390274 | Twenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C. |
| Q33924165 | Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy |
| Q42999813 | Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics |
| Q36888177 | Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling |
| Q34788754 | Very early prediction of response to HCV treatment with PEG‐IFN‐alfa‐2a and ribavirin in HIV/HCV‐coinfected patients |
| Q27478062 | Viral Determinants of Resistance to Treatment in Patients with Hepatitis C |
| Q26824655 | Viral kinetic modeling: state of the art |
| Q43042510 | Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients? |
| Q33675362 | Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients |
| Q36562168 | Viral kinetics in the treatment of chronic hepatitis C. |
| Q34062108 | Viral kinetics of enterovirus 71 in human abdomyosarcoma cells |
| Q34251341 | Viral kinetics suggests a reconciliation of the disparate observations of the modulation of claudin-1 expression on cells exposed to hepatitis C virus |
| Q34714349 | Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection |
Search more.